Morepen Laboratories Ltd Q2 FY26 – APIs on Fire, Devices in Detox, and a 2,472-Lakh “Exceptional Gain” that Raised Eyebrows

1. At a Glance

If pharmaceutical drama had an IPL version, Morepen Laboratories Ltd would be the team that suddenly drops its star player mid-season, raises ₹200 crore from the crowd, and then still finds a way to win a match on accounting brilliance. As of November 2025, Morepen trades at ₹44 per share, nursing a market cap of ₹2,402 crore, and a bruised ego after a -40.5% YoY return.

The September 2025 quarter (Q2 FY26) wasn’t exactly “Doctor’s Delight” either — Revenue stood at ₹412 crore (down 5.97% QoQ) and PAT crashed 49% to ₹17.8 crore. The stock’s P/E sits at 31.8x, meaning investors are still paying luxury prices for a company that just pulled off an “exceptional gain of ₹2,472.95 lakh” while losing control of Dr. Morepen Ltd in July.

Operating margin fell back to 7%, ROE is 11.8%, ROCE 15.1%, and debt crept up to ₹158 crore. Yet, with 53 granted patents, 1,750 million Gluco Strips sold, and 6.33 million BP monitors pumping data, Morepen remains India’s OG of “Doctor G meets Excel Sheet”.

2. Introduction

Let’s start with a confession — few pharma companies have aged as dramatically as Morepen Labs. This is the same brand that once sold Burnol for your burns and now seems to apply it metaphorically to its own financial wounds.

The market once loved its “Dr. Morepen” tag for health devices, but somewhere between COVID-era sugar tests and post-pandemic hangovers, the stock’s glucose levels spiked and then crashed faster than a bad HbA1c reading.

Despite the melodrama, the company has a legitimate empire: API manufacturing, branded formulations, and medical devices. It’s a rare small-cap that plays in both chemistry and cardiology, exporting to 80+ countries while also selling BP monitors on Flipkart flash sales.

In FY25, it hit its highest-ever PAT of ₹118 crore — and even declared a dividend for the first time in 23 years. But Q2 FY26 reminded everyone that the pharma business isn’t a treadmill — it’s a blood-pressure monitor; one quarter up, the next flatlining.

Will Morepen’s big push into medtech (through its new subsidiary Morepen Medtech Ltd) and Dubai expansion be the statin shot it needs? Or will it keep popping “accounting vitamins” while the real growth remains in clinical trials? Let’s find out.

3. Business Model – WTF Do They Even Do?

Morepen’s business is split like a medical textbook:

1️ Pharma Business (70% of H1 FY25 revenue):
The heart of the company, literally and financially. Within this, the API segment contributes about 75%. Think of APIs (Active Pharmaceutical Ingredients) as the base masala for the world’s drug biryani — and Morepen is the chef who supplies the spice mix.

The company dominates in six key molecules:

• Montelukast (70% market share) – the anti-asthmatic star.
• Loratadine & Desloratadine (69% and 49%) – anti-allergy kings.
• Fexofenadine, Atorvastatin, Rosuvastatin – the cholesterol warriors.

Together, these account for over 80% of its API revenue. Morepen has mastered the art of “generic domination” — low glamour, high export, and stable cash.

2️ Finished Formulations & OTC (25% of Pharma):
This segment is where the Dr. Morepen brand flexes. From Lemolate (the desi Vicks challenger) to Burnol (the meme legend), these products fill pharmacies and first-aid kits across India.

3️ Medical Devices (30% of revenue):
Welcome to the home-health circus — glucometers, BP monitors, oximeters, thermometers — basically everything your gym trainer ignores. This segment grew 9.35% YoY in H1 FY25, led by the iconic GlucoOne brand.

The twist? In Jan 2025, the company decided to spin off this devices division into a new subsidiary, Morepen Medtech Ltd, citing focus and “value unlocking”. Translation: “We’ll list it separately when the market mood improves.”

So, what does Morepen actually do? Everything from chemistry to cardiology, from glucose strips to global patents. It’s like a doctor with a second income as an engineer.

4. Financials Overview

Commentary:
This quarter’s financials look like a patient with irregular heartbeat — Revenue down, profit